As part of scheme to triple rev­enue this year, AGC adds on to Spain site for HPA­PIs

An AGC sub­sidiary in Eu­rope will get a $100 mil­lion in­vest­ment to add on a new build­ing at the site, and add an ex­pan­sion for the man­u­fac­tur­ing of high­ly po­tent ac­tive phar­ma­ceu­ti­cal in­gre­di­ents.

The move is a part of the medi­um-term man­age­ment plan dubbed AGC plus-2023. The group is look­ing to grow its busi­ness from $361 mil­lion to $1.08 bil­lion this year, and to $1.6 bil­lion by the year 2025. These am­bi­tions, while lofty, are aligned to keep the com­pa­ny on track with the grow­ing de­mand of the glob­al phar­ma­ceu­ti­cal CD­MO mar­ket, which has grown more than 7% each year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER